HROW: harrowinc.com Revenue Growth QoQ

Harrow, Inc. is aggressively capturing the US ophthalmology market by replacing scarce alternatives with its own products. The GURU.Markets portal features a chart of quarterly sales growth, where 38.40 reflects the latest metric value. This growth is driven by the development of convenient combination drugs, although strict prescription regulations and intense competition in the eye drop segment hinder further expansion.
Analytical breakdowns for Harrow (HROW)

The indicator calculates the percentage change in total revenue between the current and previous quarters, revealing the actual expansion dynamics of the issuer's commercial presence. Growth in this metric confirms the effectiveness of Harrow, Inc. (HROW) expansion within the ophthalmology drug segment and the development of its specialized pharmacy network, clearly reflecting the quarter-over-quarter revenue growth rate.